CD15s和nm23H1表达与肝细胞癌临床病理特征的关系  

Correlations between Expression of CD15s and nm23H1 and Clinicopathologic Features of Hepatocellular Carcinoma

作　　者：蒋童新 尚培中[2] 王华 潘虹霞[2] 尚丹丹 张利萍[2] 裴树俊[2] 王金[2] 王铁山[2] 马跃燕[2] 李伟[2] 谷化平[2] JIANG Tong-xin;SHANG Pei-zhong;WANG Hua;PAN Hong-xia;SHANG Dan-dan;ZHANG Li-ping;PEI Shu-jun;WANG Jin;WANG Tie-shan;MA Yue-yan;LI Wei;GU Hua-ping(Department of General Surgery,Tongji Hospital of Huailai,Huailai,Hebei 075400,China;Department of General Surgery,The 251 st Hospital of PLA,Zhangjiakou,Hebei 075000,China;The First Training Team of Soldier Undergraduates,Communication Training Base of Army,Beijing 102400,China)

机构地区：[1]河北怀来同济医院普通外科,河北怀来075400 [2]中国人民解放军第251医院普通外科,河北张家口075000 [3]陆军通信训练基地学兵训练一队,北京102400

出　　处：《河北北方学院学报（自然科学版）》2018年第10期1-4,8,共5页Journal of Hebei North University:Natural Science Edition

摘　　要：目的探讨CD15s和nm23H1在肝细胞癌(HCC)组织中的表达及其与临床病理特征的关系。方法应用免疫组化染色EliVisionTM plus两步法检测150例HCC组织中CD15s和nm23H1的表达,分析其与HCC转移率、分化程度及患者5年生存率的关系。结果 CD15s和nm23H1在HCC组织中阳性表达率分别为39.3%和61.3%。CD15s在低分化的HCC中阳性率为47.8%(43/90),在高分化的HCC中阳性率为26.7%(16/60);在有转移的HCC中阳性率为53.7%(36/67),在无转移的HCC中阳性率为27.7%(23/83);在术后5年内死亡的HCC患者中阳性率为59.1%(39/66),在术后生存满5年以上的HCC患者中阳性率为33.3%(8/24)。上述3项比较差异均有统计学意义(P<0.05)。nm23H1在低分化的HCC中阳性率为44.4%(40/90),在高分化的HCC中阳性率为86.7%(52/60);在有转移的HCC中阳性率为40.3%(27/67),在无转移的HCC中阳性率为66.3%(55/83);在术后5年内死亡的HCC患者中阳性率为22.7%(15/66),在术后生存满5年以上的HCC患者中阳性率为79.2%(19/24)。上述3项比较差异均有统计学意义(P<0.05)。CD15s的表达与nm23H1的表达呈负相关(r=-0.54)。结论 CD15s和nm23H1的表达与HCC分化程度、浸润转移和患者生存期密切相关,联合检测CD15s和nm23H1的表达可作为评估HCC预后的参考指标。Objective To investigate the correlations between expression of CD15s and nm23H1 and clinicopathologic feature of hepatocellular carcinoma（HCC）. Methods EliVision TM plus two-step immunohistochemical method was used to detect the expression of CD15s and nm23H1 in 150 cases of HCC.The correlations between the expression and hepatocellular metastatic rate,differentiation degree and 5-year survival rate were analyzed. Results The positive expression rates of CD15s and nm23H1 in HCC tissues were 39.3% and 61.3% respectively.The positive rate of CD15s was 47.8%（43/90）in poorly differentiated HCC,26.7%（16/60）in well-differentiated HCC;the positive rate of CD15s was 53.7%（36/67）in metastatic HCC,27.7%（23/83）in non-metastatic HCC;the positive rate of CD15s was 59.1%（39/66）in HCC patients who died within 5 years after operation,33.3%（8/24）in HCC patients over 5 years after operation;the difference was statistically significant （P 〈0.05）.The positive rate of nm23H1 was 44.4%（40/90）in poorly differentiated HCC,86.7%（52/60）in well-differentiated HCC;the positive rate of nm23H1 was 40.3%（27/67）in metastatic HCC,66.3%（55/83）in non-metastatic HCC;the positive rate of nm23H1 was 22.7%（15/66）in HCC patients who died within 5 years after operation,79.2%（19/24）in HCC patients over 5 years after operation;the difference was statistically significant（ P 〈0.05）.The expression of CD15s was negatively correlated with the expression of nm23H1 （r =-0.54）. Conclusion The expression of CD15s and nm23H1 were closely correlated with differentiation degree,invasion-metastasis and patient survival period in HCC.Combined detection of CD15s and nm23H1 expression can be used as indicators to evaluate the prognosis of HCC.

关 键 词：肝细胞性肝癌 CD15S NM23H1 肿瘤转移 

分 类 号：R735.7[医药卫生—肿瘤]